Sofia, 1407, Bulgaria
Biotechnology
micar21.com

Drugs are getting more expensive to develop. These days, it takes about few millions and 10 years for a single new drug. Simulating millions of virtual drugs to find potential commercial candidates in weeks? That what we call truly transformative.

Micar Innovation aims to change that by using all novel advanced approaches supported also by own drug discovery screen technology and GPU power to predict, in advance, which potential drug candidate molecule will work, and which won't. The same is valid for an innovative cosmetics active substance. Our technology can tell the difference between great drug candidates and toxic ones, and discover new uses for old medicines. The result is fewer test tubes, fewer experiments, fewer failed drugs. Just new and better medicines, faster. Micar Innovation can help discover and than predict the effectiveness of new potential drug molecules, reducing the need for costly and time-consuming physical synthesis and testing.
With Micar Innovation rapid growth comes opportunities for organizations seeking new medicines or cosmetics active substances to work with the company. Micar Innovation is now inviting proposals for drug discovery collaborations from both private and public institutions. The company is also actively recruiting in the multidisciplinary areas of big data, bio informatics, computational biology, molecular dynamics, molecular modeling, medicinal chemistry, sctructural biology, precise free energy calculations, business development, sales and partnerships.
Own unique technology in a combination with all available advanced analysis, powered by GPU power, identifies new drug.
Our own technology included multidisciplinary sciences and our we have many scientific publications. The same technology work not only for humans new drug, we use our technology for medicinal cosmetics and for animal drugs.

General Information

 
 
 
 
 

Social Links

Company Industry

Select Industry:

Company Description

0 / 250
 
0 / 2000
 

Summary

Prior Year Revenue Current Year Revenue Next Year Revenue
Company Age Employees Sub-Industry
1 year, 10 months 3 Other Biotechnology
Company Type Stock Exchange Stock Symbol
Privately-Held - -

Company Financials

Viewable by EquityNet investors only

Company Age & Size

Stock Exchange

Is this company privately-held or publicly-traded?

Products / Services

0 / 1000
Personalized genetics screen analysis by novel advanced approaches

Personalized genetic screen analysis by novel advanced approaches

We bring to the ordinary people advanced information obtained by high-end technology. Based on a DNA test, we can provide:

significant information about how an identified mutation alters protein structure and functions;
answer at a highly sufficient level the question whether it is a disease-causing mutation or not;
inform you whether existing drugs, if any, can influence your particular case (mutation);
propose experimental treatment and even natural products that might help physicians in case no approved drugs exist;
propose an individual project for each client;

This has implications for many bioinformatics prediction tools such as SIFT and PolyPhen, as these tools largely rely on residue conservation (i.e. whether one mutation is common to many species or not), limiting the use of conservation-based tools.

.....

In silico drug design - screening for biological active compounds

In silico drug design helps to greatly reduce both the time and cost of your project without any compromise of the accuracy.

One of the main challenges facing modern drug design is to find new biologically active lead compounds, i.e. those which can bind to a target protein, and to reduce the price for such a project. For instance, if one tries to screen a library of 200 000 compounds, one will have to spend about 20 million US dollars only for these chemicals and much more for the other necessary reagents. Even screening of an inefficiently small collection of 2000 compounds will cost about 200K dollars for the chemicals.

In silico drug design helps to greatly reduce both the time and cost of your project. It comprises a vast number of advanced scientific computational techniques and resources. Therefore, in silico drug design is not only a powerful tool for discovering novel potential drugs, but it can also lead to a ........

Drug discovery faster

Medicines are getting more expensive to develop. These days, it takes about few millions and 10 years for a single new drug. Simulating millions of virtual medicines to find potential commercial candidates in weeks? That what we call truly transformative.

Micar Innovation aims to change that by using all novel advanced approaches supported also by own drug discovery screen technology and GPU power to predict, in advance, which potential drug candidate molecule will work, and which won't. The same is valid for an innovative cosmetics active substance. Our technology can tell the difference between great drug candidates and toxic ones, and discover new uses for old medicines. The result is fewer test tubes, fewer experiments, fewer failed drugs. Just new and better medicines, faster. Micar Innovation can help discover and than predict the effectiveness of new potential drug molecules, reducing the need for costly and time-consuming physical synthesis and testing.

Management

0 / 1000
Managing Director Research & Development
Filip Fratev

Filip FratevLeader of the scientific team and one of the founders of Micar 21 Ltd. B.S. in Chemistry, M.S. in Physics, Ph.D. in Computational Chemistry and in silico bio-simulations and drug design.

Filip has more than 10 years’ experience in the above scientific fields and has worked for more than 7 years in highly qualified academic institutes and universities in E.U: Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy; Technical University of Denmark, Center for Biological Sequence Analysis, Copenhagen, Denmark; University of Bergen, Department of Molecular Biology, Bergen, Norway; Bulgarian Academy of Sciences, Institute of Biophysics and Biomedical Engineering, Sofia, Bulgaria.
He has published more than 15 papers, as a first author, and a book chapter that has received more than 100 citations.
-----
He is the leader of the divisions that perform molecular dynamics studies, protein modeling and docking screening.

Managing Director Business Development
Dimitar Dimitrov

Dimitar DimitrovLeader of the IT software team and one of the founders of Micar 21 Ltd. Dimitar has more than 20 years’ experience in the software development. His clients are governments, academic institutes and universities in EU and USA.
updates on 28 Feb 2015

Funding

To find out if this company and others are accepting funding, .

Funding Goal

Funding Raised So Far

Funding Commitments

Funding Remaining

Funding Type

Pre-Money Valuation

Investor Ownership

Interest / Dividend

Previous Funding

General Funding

Showing your General Funding information publicly may constitute general solicitation. General solicitation is a new commonly-used way for companies to raise funding. To learn about general solicitation, consult your legal counsel. If you uncheck this box, your General Funding information will be viewable to only EquityNet investors.

Private Funding

Viewable by EquityNet investors only

Video

Micar21 Image 1
Micar21 Image 2
Micar21 Image 3

Images

Documents

Complete a Business Plan in EquityNet

Your EquityNet business plan is only viewable to capital providers and business supporters that you choose to share with in the “Crowdfund” or “Messages” tab. Investors prefer an EquityNet business plan. Entering a plan is highly educational and improves your appeal to investors.

Upload Documents

Document file names will be viewable by EquityNet investors and business supporters only. Actual documents are only viewable to capital providers and business supporters that you choose to share with in the “Crowdfund” or “Messages” tab.

Share Your Public Profile Page

Users who follow all these tips increase their fundraising odds substantially.

  • Email your public page to all your LinkedIn contacts.
    • Post your page to your LinkedIn profile page.
  • Email your public page to all your Facebook contacts.
    • Post your page to your Facebook profile page.
  • Email your public page to all your Twitter contacts.
    • Post your page to your Twitter profile page.
  • Put your public page up on your website.
    • Don't have a website yet? Use this page as your site!
  • Share your page link anywhere there's a listing for your company.
    • Press Releases, Crunchbase, Wikipedia, Blogs, etc...
  • Email your public page to all your email contacts.
    • Use Outlook, Gmail, Yahoo Mail, Hotmail, etc...

Your Public Profile Page:

Would you like to share your public profile page with your email contacts?